Kornimate/medical-research-clean huggingface dataset:
impact of giving birth during the covid 19 pandemia on postnatal women's depression

Conditions: Postnatal Depression

Summary: postnatal depression is an important problematic in french population with approximatively 10 -20% of women who suffer from postnatal depression. this pathology may have strong negative impact on both women and neonate's health. the women's satisfaction degree in front of childbirth is an important factor associated with postnatal depression since women unsatisfied of their childbirth and/or women with a complicated childbirth are more encline to suffer from postnatal depression. it is likely that the actual context of covid 19 pandemia and the change in obstetrical cares organization may have a negative impact on women's satisfaction about their childbirth and so a negative impact on the risk of postnatal depression.


Eligibility criteria:
inclusion criteria: * women older than 18 years * women who deliver of a singleton, term neonate in cephalic presentation exclusion criteria: * women younger than 18 years * women who deliver of a baby in non cephalic presentation * women with pre term birth * women without any internet access * women with psychiatric disorders * women who do not understand french language * women who refuse to be aware of the results of the postnatal depression screening and who refuse that her doctor be ware of the results

Keywords: childbirth covid 19 satisfaction
remodelling after trampoline fracture in children

Conditions: Trampoline Fracture; Tibial Fracture

Summary: the anterior tilting of the proximal tibia epiphyseal plate is a radiological tool for the diagnosis of suspected trampoline fracture. the tibial fracture leads to a ventral tilting of the tibial plateau. this study is to document the long-term follow-up of the anterior tilt angle and to verify, if there is an uplift of the tibia plateau with correction of the anterior tilt angle to normal values (= remodelling) in order to guarantee optimal treatment of this rare fracture.


Eligibility criteria:
inclusion criteria: * trampoline fracture of the proximal lower leg exclusion criteria: * proximal tibial fractures with unclear etiology

Keywords: ventral tilting of the tibial plateau anterior tilt angle proximal tibia epiphyseal plate
pharmaceutical follow-up of coronary heart disease (chd) patients

Conditions: Coronary Heart Disease

Summary: objectives to explore the impact of a clinical pharmacist-led 12 month lasting follow-up program for patients with established coronary heart disease (chd) discharged from the north norway university hospital. methods a total of 102 patients aged 18-82 years were enrolled in a non-blinded, randomized controlled trial. the intervention comprised medication reconciliation, medication review and patient education during three meetings; at discharge, after three months and after twelve months. the control group received standard care from their general practitioner. primary outcomes were adherence to clinical guideline recommendations concerning prescription, therapy goal achievement and lifestyle education defined in the medication assessment tool for secondary prevention of chd (mat-chdsp). secondary outcomes included changes in the biomedical risk factors cholesterol, blood pressure and blood glucose. key findings ninety-four patients completed the trial, 48 intervention group patients and 46 controls. appropriate prescribing was high, but therapy goal achievement was low in both study groups throughout the study. overall adherence to mat-chdsp criteria increased in both groups and was significantly higher in the intervention group at study end compared to the control group, 78.1% vs. 61.4%, p \< 0.001. the difference was mainly due to an increased documentation of lifestyle advices in intervention group patients. no significant improvements in biomedical risk factors were observed in favor of the intervention group, possible due to an underpowered study. conclusion the clinical pharmacist-led follow-up program significantly increased documented lifestyle advices defined in the mat-chdsp for the intervention group, but did not lead to significant improvements in biomedical risk factor measures in favor of the intervention group. even if prescribing was high, therapy goal achievement was low in both study groups. changes to the follow-up program are warranted, in addition to a larger, adequately powered study, before implementation in standard patient care can be recommended.

find published article in pharm pract (granada). 2015 apr-jun; 13(2): 575. https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4482847/pdf/pharmpract-13-575.pdf

Eligibility criteria:
inclusion criteria: * established coronary heart disease * age 18 - 80 years * patients living in the three nearby communities tromsoe, balsfjord and karlsoey, this because they need to see the pharmacist personally. exclusion criteria: * patients living in nursing homes * patients included in norstent, another trial including patients at the same department * patients already receiving pharmaceutical follow-up elsewhere * cancer patients

Keywords: preventive health services
non-invasive liver screening using fibroscan device for liver disease patients for the steatosis/fibrosis database

Conditions: Disease of Liver and Bile Duct

Summary: the primary goal of this study is to establish a database of people with varying levels of hepatic fibrosis and various etiologies of liver disease for use in future research protocols.

the fibroscan device will determine liver stiffness as well as the amount of fat through another application on the machine called controlled attenuation parameter or controlled attenuation parameters (cap). the liver stiffness measurements are then translated into a score that tells how much liver fibrosis or fat is present. patients identified with potential for fatty liver or specific liver-related diseases causing fibrosis would be approached for a voluntary fibroscan measurement. from these patients, the investigators will collect information related to demographics, disease history, medical comorbidities, social history, laboratory and radiologic parameters. this information, along with clinical data associated with the patient will be placed in a database for use in identifying potential subjects for future trials.

Eligibility criteria:
inclusion criteria: * subjects with known, or suspected risk factors for steatosis (fat) or hepatic fibrosis * subjects who have been previously diagnosed with non-alcoholic steatohepatitis (nash) but who do not have current steatosis (fat) or fibrosis scoring * subjects who have other known liver diseases ie: hcv exclusion criteria: * patients less than 18 years of age * pregnancy * patients that do not want to be contacted for consideration in future research studies. * patients diagnosed with ascites or peritoneal dialysis * body mass index (bmi) ≥40
efficacy and safety of intravitreal vascular endothelial growth factor trap-eye in patients with polyploidal choroidal vasculopathy

Conditions: Polypoidal Choroidal Vasculopathy Without Active Polyp

Summary: the purpose of this study is to evaluate the efficacy and safety of aflibercept for treatment of polypoidal choroidal vasculopathy without active polyp.


Eligibility criteria:
inclusion criteria: * polypoidal choroidal vasculopathy without active polyp * decreased visual acuity by subretinal fluid and hemorrhage involving foveal center exclusion criteria: * polypoidal choroidal vasculopathy with active polyp * previous photodynamic therapy more than three times * anti-vegf injection within one month * photodynamic therapy or intraocular steroid treatment within three months
index of microcirculatory resistance after immediate versus deferred stenting in patients with acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: this study will compare the microcirculatory resistance (imr) of infarct-related artery (ira) in patients who underwent immediate versus deferred stenting during percutaneous coronary intervention (pci) for acute myocardial infarction.

primary pci with immediate stenting (is) is the current standard of reperfusion strategy for stemi. however, it is thought that is may cause additional myocardial injury by increasing distal embolization of clot and atheromatous plaque debris. only about 35% of patients without cardiogenic shock can achieve optimal myocardial tissue perfusion at the microvascular level, even after restoration of epicardial coronary artery patency. is in highly pro-thrombotic and inflammatory milieu of ira during primary pci would increase distal embolization of clot and atheromatous plaque debris, and provoke the inflammation process, so deferred stenting after a cooling down period of ira for several days, have a potential to mitigate or prevent microvascular obstruction (mvo). among several methods to evaluate mvo after stemi, imr has been well known as an good indicator of mvo and strong predictor for short and long term clinical outcomes.

Eligibility criteria:
inclusion criteria: 1. more than 30 minutes in duration of typical chest pain 2. thrombolysis in myocardial infarction (timi) flow 0, 1 or 2 prior to the procedure exclusion criteria: 1. cardiogenic shock, 2. previous history of myocardial infarction, or coronary artery bypass surgery 3. rescue pci after fibrinolysis 4. life expectancy of less than 1 year 5. acute occlusion of left main coronary artery 6. stemi due to stent thrombosis 7. major coronary dissection (type d\~f) following procedures achieving timi 3 flow

Keywords: deferred stenting microvascular dysfunction
companion dog walking for icu survivor health

Conditions: Post Intensive Care Syndrome; Depression; Anxiety; Quality of Life

Summary: the goal of this clinical trial is to determine the feasibility and acceptability of a randomized controlled trial comparing a pet dog walking intervention to an attention control education intervention in adult intensive care unit survivors. the main question\[s\] it aims to answer are: * what is the feasibility of a pet dog-walking intervention compared to an attention control education intervention on depression, anxiety, cortisol, and quality of life for adult icu survivors. * what is the acceptability of a pet dog-walking intervention compared to an attention control education intervention on depression, anxiety, cortisol, and quality of life for adult icu survivors. the secondary question\[s\] it aims to answer are: - what are the differences in depression, anxiety, serum cortisol, and quality of life between and within a companion dog walking intervention compared to an attention control education intervention for icu survivors? participants in the intervention group will be asked to: * participate in dog walking with their pet dog at least three times per week, for at least 10 minutes each walk, for 8-weeks. * wear an activity monitor and record their dog walks in a diary. * complete surveys to measure depression, anxiety, and quality of life at the start of the study, after week 4, and after week 8. * have blood drawn to measure cortisol levels at the start of the study, after week 4, and after week 8. participants in the control group will be asked to: * read educational materials about their pet dog's health once every week (education materials are provided by the researchers). * wear an activity monitor and record when they read their education materials in a diary. * complete surveys to measure depression, anxiety, and quality of life at the start of the study, after week 4, and after week 8. * have blood drawn to measure cortisol levels at the start of the study, after week 4, and after week 8. participants will be assigned to an intervention group or a control group to see if there are differences in depression, anxiety, serum cortisol, and quality of life.


Eligibility criteria:
inclusion criteria: * adult (≥18 years) * icu survivors (spent ≥24 hours in the icu) * will be discharged directly home from hospital. * able to speak, read, and understand english * physically capable of dog walking * individuals who have symptoms of depression and/or anxiety * individuals who own a companion dog and walk their dog \<10 minutes/week * participants scoring ≤ 20 seconds on the tug test exclusion criteria: * individuals at high risk for suicide * individuals with severe depression or anxiety * individuals who recently started treatment for depression and/or anxiety * individuals with cognitive impairment * dog walking is deemed unsafe with and for the dog * medical provider authorization is indicated but not provided * individuals who live outside a 45-mile radius of colorado springs.

Keywords: post intensive care syndrome icu survivors companion dog depression anxiety quality of life
scs research study

Conditions: Limb Pain; Trunk Pain

Summary: to characterize the effects of stimulation parameters on pain relief and other cohort specific outcomes.


Eligibility criteria:
inclusion criteria: 1. 22 years of age or older 2. implanted with a medtronic rechargeable neurostimulation system, for a labeled indication, for at least 1 month and expected longevity of neurostimulator is at least 5 months 3. willing and able to provide signed and dated informed consent 4. capable of comprehending and consenting in english 5. willing and able to comply with all study procedures, including diary completion, and visits 6. able to differentiate between pain associated with the indication for scs implant and other types of pain exclusion criteria: 1. implanted with neurostimulation system for an off-label indication 2. currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results 3. if female, pregnant or is of child-bearing potential and unwilling to use a medically acceptable form of birth control during the study 4. has untreated major psychiatric comorbidity 5. has a non-rechargeable neurostimulator where the battery longevity is not able to be estimated with the battery longevity calculator
vitamin d supplementation in chronic rhinosinusitis with nasal polyps

Conditions: Chronic Sinusitis

Summary: the purpose of this study is to determine if vitamin d supplementation improves clinical and immunologic parameters in chronic rhinosinusitis with nasal polyps.

introductory statement: our laboratory has found that patients with chronic rhinosinusitis with nasal polyps (crswnp) have insufficient levels of vitamin d3. this is a proposal to conduct a placebo controlled trial on the use of vitamin d3 (5,000iu/day for 6 weeks) to determine clinical and immunologic outcomes in these patients. general investigational plan: we routinely examine vitamin d levels in all patients with crswnp. those that are insufficient (less than 32 ng/ml) and have agreed to undergo sinus surgery will be randomized to placebo or vitamin d3 supplementation (5,000iu/day) for 6 weeks prior to surgery. blood will be drawn pre- and post-supplementation to examine systemic immune parameters such as dendritic cell and t cell expression and cytokine levels. sinus tissue will be collected at the time of surgery to analyze local immune parameters (dendritic cell, t cell and cytokine levels) between supplemented and placebo groups. clinical outcomes will be analyzed using quality of life questionnaires, endoscopic grading and nasal peak inspiratory flow pre- and post- supplementation. irb approval for this research project is pending.

Eligibility criteria:
inclusion criteria: * chronic sinusitis with polyps exclusion criteria: * use of systemic steroids, or other immunmodulatory agents in preceding months, other immunologic, renal, gastrointestinal, endocrine or skeletal disorder (rheumatoid arthritis, immunodeficiency, cystic fibrosis, ciliary dyskinesia, malabsorption, etc.) * pregnancy or age less than 14 years.

Keywords: sinusitis chronic sinusitis with polyps
contextualizing & responding to hiv risk behaviors

Conditions: Human Immunodeficiency Virus

Summary: the purpose of this study was to pilot test the potential for improvement in antiretroviral medication adherence of a an adapted group-based, multi-session, community-based antiretroviral therapy (art) adherence and risk reduction intervention, project adherence education and risk evaluation (adhere). project adhere was compared to a single-session group-based medication adherence intervention, medication adherence and care engagement (mace). a secondary aim was to examine the impact of project adhere on hiv risk behaviors (i.e., illicit drug use and unprotected sexual behavior). this study was designed to inform, design, and pilot test the two antiretroviral medication adherence interventions for hiv-infected formerly incarcerated individuals.

formerly incarcerated black drug offenders are at an elevated risk for hiv infection. despite substantial research expressing the need for hiv prevention services for ex-offenders postrelease, this population has limited access to quality programming and services related to hiv risk reduction. this k01 application seeks to inform and adapt an hiv risk reduction intervention to address the needs of formerly incarcerated black drug offenders who are being released from prisons in the new york city metropolitan area.the study will utilize qualitative and quantitative methods to inform and adapt an hiv prevention intervention for this study population.

Eligibility criteria:
inclusion criteria: 1. ≥18 years of age 2. hiv seropositive with "detectable" viral load (vl)(defined as \>50 copies/ml) 3. history of drug use (used illicit drugs within the past year) 4. experienced incarceration in prison or jail within the past five years exclusion criteria: 1. living in a healthcare or assisted living facility 2. experienced incarceration longer than five years ago
bacille calmette-guerin (bcg) vaccine for immune protection against infections

Conditions: Cystic Fibrosis; Bronchiectasis Adult; Non-Tuberculous Mycobacteria

Summary: this is pilot study of the immunologic effects of intradermal bacille calmette-guerin (bcg) vaccination of adults with cystic fibrosis (cf), non-cf bronchiectasis (ncfb), and healthy volunteers.

this single-site, open-label clinical trial to investigate the immune effects of bcg vaccination in adults with cystic fibrosis, non-cystic fibrosis bronchiectasis and healthy volunteers by measuring pre and post vaccination immune responses, bcg uptake and protection against infections, including nontuberculous mycobacteria (ntm). this study will also gather data on study feasibility, tolerability, and safety.

Eligibility criteria:
inclusion criteria (cf and non-cf bronchiectasis): * confirmed diagnosis of either cf or non-cf bronchiectasis * forced expiratory volume over one second (fev1) \> 40% * willingness to participate in the study after all aspects of the protocol have been explained and written informed consent obtained. * available for the study duration, including all planned follow-up visits inclusion criteria (healthy volunteers): * negative hiv enzyme-linked immunosorbent assay (elisa) and confirmatory test at screening. * willingness to participate in the study after all aspects of the protocol have been explained and written informed obtained. * available for the study duration, including all planned follow-up visits exclusion criteria (all arms): * current or prior history of active or latent tuberculosis (tb) (per report, not formally tested) or ntm infection * prior bcg vaccination * previous vaccine in the past 4 weeks * history of severe anaphylaxis to any vaccine or vaccine components * history of organ/bone marrow transplantation or other immunosuppressing condition, including hiv * immunosuppressing drugs (including oral corticosteroids equivalent to \>10mg of prednisone for 5 days) in the 30 days prior to study enrollment * cirrhosis or portal hypertension * pregnant or breastfeeding * receipt of another investigational product in the last 28 days or planned receipt during this study * has any other condition that, in the opinion of the principal investigator, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives.

Keywords: bcg vaccine cystic fibrosis bronchiectasis non-tuberculosis mycobacteria
a prospective cohort study for establishing clinical excellence in patients with newly diagnosed type 1 and type 2 diabetes and prediabetes

Conditions: Newly Diagnosed Type 1 and Type 2 Diabetes and Prediabetes

Summary: diabetes mellitus is recognized as a metabolic disease that causes global economic and health burdens with an estimated number of patients 135 million in 1995 to 300 million in 2025. moreover, the asia-pacific region is considered to be on the verge of an emerging diabetes epidemic. diabetes is associated with numerous comorbidities due to a wide range of complications, such as retinopathy, nephropathy, neuropathy, and cardiovascular disease, which could lead to premature mortality. management of diabetes under standard treatment protocol improves quality of life and prevents complications and premature mortality. pathogenesis of these detrimental complications caused by diabetes is not yet discovered and it is important to reveal epidemiology and mechanisms of diabetes and its complications in order to successfully manage and control diabetes. according to the committee of the korean diabetes association on the epidemiology of diabetes mellitus, only about one third of patients with diabetes was found to reach target glycemic control (\<7% of hba1c) and 30.3%, 38.3% and 44.6% of patients found to have microalbuminuria, retinopathy and nephropathy, respectively in tertiary hospitals of korea in 2006. also, prevalence of coronary artery disease, cerebrovascular disease and peripheral artery disease was 8.7%, 6.75 and 3.0%, respectively in tertiary hospitals. due to inadequate achievement of glycemic control and improper prevention tactics to prevent diabetic complication for patients in tertiary hospitals in korea, it is pivotal to determine and analyze the current status of patients with diabetes and prediabetes for efficient management of diabetes/prediabetes and its complications. annual visits of newly diagnosed diabetes or prediabetes to endocrinology department of severance hospital in korea are increasing, about 5,000 patients per year since 2017. however, there is no current systemic clinical registry involving patients with diabetes or prediabetes in severance hospital. therefore, in this prospective cohort study, we will establish registry for patients with diabetes or prediabetes who would perform standard blood/urine tests and follow treatment protocols in endocrinology department of severance hospital.


Eligibility criteria:
inclusion criteria: * drug naive patients who are newly diagnosed type 1 diabetes/type 2 diabetes or prediabetes since march, 2022 in severance hospital ② male or female who are older than 20 years ③ patients who consented and underwent recommended regular blood and urinary tests according to the current guidelines. exclusion criteria: ① patients who are considered to be unable to participate in the study by the judgement of researchers ② patients who are unable to read the consent forms (e.g foreigner, illiteracy)